# 2nd Annual BREAST CANCER SYMPOSIUM

Controversies in Breast Cancer: Increasing or Decreasing?

PROUDLY HOSTED BY
NEW YORK ONCOLOGY HEMATOLOGY





Maria Theodoulou, MD
Course Chair and Moderator
New York Oncology Hematology

## September 25-26, 2020

## LIVE Online Event

This activity has been approved for 11 AMA PRA Category 1 Credits™

The Conference is being held in Eastern Daylight Time

Friday,	September 25th, 2020	
10:00 AM	EXHIBITS & PRE-COURSE ANCILLARY EVENTS	
12:00 PM	Welcome, Opening Remarks & Arena Survivorship Award	Dr. Maria Theodoulou (NYOH)
12:30 PM	COVID19 & The Physician	Dr. Mark Citron (ProHEALTH)
1:00 PM	Breast Imaging: Current & Future	Dr. Elizabeth Morris (MSKCC)
1:30 PM	EXHIBITS & BREAK	
1:45 PM	Community Driven Breast Imaging	Dr. Beth Whiteside (CCP)
2:15 PM	Assessing Risk for Breast Cancer & Intervention	Dr. Andrew Seidman (MSKCC)
2:45 PM	Metabolic & Energy Balance Perturbations in Breast Cancer Pathogenesis & Treatment	Dr. Neil Iyengar (MSKCC)
3:45 PM	EXHIBITS & BREAK	
4:00 PM	Advances in the Management of Hormone Positive Early Breast Cancer	Dr. Francis Arena (NYU)
4:30 PM	Hereditary Risk Factors in 2020	Dr. Mark Robson (MSKCC)
5:00 PM	Advances in the Management of Hormone Positive Breast Cancer	Dr. Claudine Isaacs (Georgetown)
5:30 PM	EXHIBITS & BREAK	
5:45 PM	Breast Cancer & The Older Patient	Dr. Hyman Muss (UNC)
6:15 PM	Triple Negative Breast Cancer Management in 2020: Looking Back & Looking Ahead	Dr. Tiffany Traina (MSKCC)
6:45 PM	DAY 1 CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)
6:55 PM	ANCILLARY EVENT	

Saturday, September 26th, 2020			
7:00 AM	EXHIBITS & PRE-COURSE ANCILLARY EVENTS		
8:00 AM	Opening Remarks	Dr. Maria Theodoulou (NYOH)	
8:05 AM	What To Do With The Breast & The Axilla in the Setting of Neoadjuvant in Chemotherapy: Moderated Panel Discussion: Pros and Cons	Dr. Eleftherios Mamounas (UF) Dr. George Plitas (MSKCC) Dr. Loren Rourke (US Oncology)	
8:50 AM	Breast Reconstruction in the Setting of Adjuvant Radiation	Dr. Joseph Disa (MSKCC)	
9:35 AM	Radiation Therapy After Neoadjuvant Chemotherapy	Dr. Todd Doyle (NYOH) Dr. Yasmin Hasan (UOC)	
10:35 AM	EXHIBITS & BREAK		
10:50 AM	KEYNOTE LECTURE: What is Cancer?	Dr. Larry Norton (MSKCC)	
11:50 AM	EXHIBITS, LUNCH, & ANCILLARY EVENT		
1:00 PM	Tailoring Adjuvant Therapy for Early Stage HER2+ Breast Cancer	Dr. Edith Perez (MAYO)	
1:30 PM	HER2NEU Metastatic Breast Cancer	Dr. Chau Dang (MSKCC)	
2:00 PM	DAY 2 CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)	
2:10 PM	POST-CONFERENCE ANCILLARY EVENT		

### 2nd Annual **BREAST CANCER SYMPOSIUM**

Controversies in Breast Cancer: Increasing or Decreasing?



Advances in breast cancer health have been growing exponentially during the twenty-first century and identification of novel therapeutic strategies have led to improved surgical and radiation outcomes. Actionable targets have identified smarter systemic therapies with improved, disease-free, overall survival benefits. In addition to awareness, addressing the health, emotional, and physical well-being of patients after breast cancer treatment have improved the overall quality of life for the patient and their families. As breast cancer is a multimodal disease, the purpose of this conference is to present the multiple facets that constitute the individual patient's diagnosis, management, and treatment. The goal of this conference is to educate the medical and global community in a forum to foster communication that will benefit the individual patient as well as the community.

#### **TARGET AUDIENCE**

Medical, surgical, and radiation oncologists as well as primary care physicians, gynecologists, medical professionals and health care professionals with an interest in breast cancer are invited to attend.

#### **LEARNING OBJECTIVES**

After completing this activity, participants will be able to:

- Review the modern surgical approaches addressed in the patient encounter
- Discuss updates in breast cancer imaging for earlier detection
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2neu overexpressing and triple negative breast cancer
- Review advances in radiation therapy and outcomes
- Identify risk factors and endocrine interventions in patients high risk for developing breast cancer
- Discuss the role of hereditary genetics and the implication to the patient and their families

#### **CONFERENCE PLATFORM**

The 2nd Annual Breast Cancer Symposium is being held online utilizing a multimedia webcast and virtual conference platform to livestream the keynote, plenary sessions and ancillary events along with moderated Q&A panel discussions. The sponsors and exhibitors of the conference will be available for attendees to visit during the duration of the conference in the Virtual Trade Show hall. The conference will be recorded and will be offered on-demand for 30 days following the conference.

#### **FEE INFORMATION**

The fee for this educational activity is \$250 for physicians and \$50 for all other allied health professionals.

#### **ACCREDITATION STATEMENT**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education



(ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and New York Oncology Hematology, PC, and in collaboration with myMedEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

#### CREDIT DESIGNATION STATEMENT

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.

#### ASSURANCE OF BALANCED, UNBIASED. AND FAIR CONTENT

**EDUCATIONAL PARTNERS** 

It is the policy of The University of Chicago Pritzker School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its individually provided or jointly provided educational activities. Individuals who are in a position to control the content of any educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.

PLANNED BY



myMedEd